Lung Research Florida

Research Facility of Advanced Asthma Clinic | Broward Pulmonary & Sleep Specialists

General Line: 954-522-7226 x1
Research Referrals: 954-520-7296 x1

Active Clinical Trials — Now Enrolling

Access the most advanced respiratory treatments available through our cutting-edge research studies. All investigational medications and study-related care provided at no cost to participants.

🔬 Ultra-Long-Acting Biologics
🧬 Dual-Pathway Targeting
🎯 Precision Medicine
8 Active Studies
$0 Cost to Participants
100% Study-Related Care Covered

AIRLYMPUS: Novel Subcutaneous Biologic for High-Risk Asthma (Mild-to-Moderate)

Study Closed — Not Currently Recruiting Severe Asthma Pre-Biologic Innovation

A new injectable biologic for severe asthma that has not responded to standard treatment. This innovative subcutaneous therapy targets inflammatory pathways in high-risk patients not yet eligible for traditional biologics, potentially preventing progression to more severe disease.

Study Overview

This 52-week Phase 2 study investigates a novel subcutaneous treatment specifically designed for high-risk asthma patients on medium-dose inhaled therapy who do not yet qualify for traditional biologics. This innovative approach targets inflammatory pathways earlier in the disease process, potentially preventing progression to severe asthma requiring more intensive treatments.

Key Study Features

  • Early Intervention: Targets inflammation in high-risk asthma not yet eligible for standard biologics
  • Subcutaneous Delivery: Convenient injection therapy
  • Exacerbation Prevention: Focus on reducing asthma attacks
  • Lung Function Improvement: Enhanced FEV1 outcomes
  • Bridge Therapy: Fills gap between standard care and biologics

Am I Eligible?

You May Qualify If You:

  • Are 18-80 years old
  • Have physician-diagnosed high-risk asthma (mild-to-moderate by GINA classification) for more than 12 months
  • Are not currently eligible for approved biologic asthma therapies
  • Had at least 1 asthma exacerbation in past year
  • Show reversibility on spirometry or have documented history

You May NOT Qualify If You:

  • Had respiratory infection within 4 weeks
  • Used anti-IgE therapy within 130 days
  • Used other biologics within 2 months or 5 half-lives
  • Are using LAMA in addition to ICS/LABA
  • Have significant other medical conditions
  • Are pregnant or planning pregnancy

Study Facts

Duration: 52 weeks
Visits: Monthly visits
Treatment: Subcutaneous injection
Design: Randomized, double-blind, placebo-controlled

Participation Benefits

  • Free investigational subcutaneous therapy
  • Regular monitoring of asthma control
  • Advanced biomarker testing
  • Comprehensive lung function assessments
  • Early access to innovative treatment
  • Close specialist monitoring
  • Compensation for time and travel

This study has completed enrollment and is no longer recruiting participants. Please see our other active trials below, or call our research line to discuss current opportunities.

IMAGINE: Ultra-Long-Acting IL-5 Therapy with Advanced CT Imaging

Now Enrolling Severe Asthma 6-Month Dosing

Fewer injections, longer-acting relief, and deep lung monitoring via CT. This revolutionary IL-5 antagonist requires only two doses per year combined with advanced CT imaging to document lung improvements. No placebo group — all participants receive active treatment.

Study Overview

The IMAGINE study is a 52-week Phase 3b trial evaluating an ultra-long-acting IL-5 antagonist administered just twice yearly. This study uses high-resolution CT scanning to document structural lung improvements over time. With no placebo group, all participants receive active treatment, making this an exceptional opportunity for patients with eosinophilic severe asthma.

Key Study Features

  • Ultra-Long-Acting: Only 2 doses per year (every 26 weeks)
  • No Placebo: All participants receive active treatment
  • CT Imaging: Visualize lung improvements over time
  • Eosinophil Control: Targets eosinophilic inflammation
  • Bronchoscopy Option: Optional substudy with lung sampling

Am I Eligible?

You May Qualify If You:

  • Are 18 years of age or older (no upper age limit)
  • Have blood eosinophils >300 cells/μL
  • Had ≥2 asthma exacerbations in past year
  • Have FeNO >25 ppb at screening
  • On medium/high-dose ICS >12 months plus controller
  • Can undergo CT scanning (no metal implants)
  • Seeking extended dosing intervals and objective lung monitoring

You May NOT Qualify If You:

  • Received anti-IL-5 therapy within 12 months
  • Failed previous anti-IL-5/5R therapy
  • Used other biologics within 12 months
  • Had exacerbation within 6 weeks
  • Have pacemaker or metal prosthesis
  • Used investigational drugs recently

Study Facts

Duration: 52 weeks
Visits: Every 3-6 months
Treatment: SC injection every 26 weeks
Special: HRCT imaging included

Participation Benefits

  • Guaranteed active treatment (no placebo)
  • Ultra-convenient 6-month dosing
  • Advanced HRCT lung imaging
  • Comprehensive biomarker testing
  • Optional bronchoscopy substudy
  • See your lung improvements on CT
  • Expert asthma specialist care
Check Your Eligibility Call Research Line Full Study Details

Lunsekimig: Sanofi Bispecific Antibody for Severe Asthma

Now Enrolling Severe Asthma Dual-Target Biologic

A Sanofi-sponsored bispecific antibody that targets two key inflammatory pathways driving severe asthma simultaneously. NCT06676319 — now enrolling adults aged 18 to 80 at Lung Research Florida.

Study Overview

Lunsekimig is an investigational bispecific antibody developed by Sanofi that targets two inflammatory mediators involved in severe asthma. By blocking both pathways with a single molecule, lunsekimig aims to provide broader, more effective control of airway inflammation in patients with persistent, difficult-to-treat asthma. This study is being conducted at Lung Research Florida under the direction of Dr. Frank Hull.

Key Study Features

  • Bispecific Design: Single antibody targeting two inflammatory pathways
  • Broad Age Range: Adults 18–80 eligible to participate
  • Sanofi Sponsor: World-class pharmaceutical company with deep respiratory expertise
  • Expert PI: Dr. Frank Hull, 20+ years of pulmonary research experience
  • No Cost: All study-related care and investigational medication provided free

ClinicalTrials.gov identifier: NCT06676319

Am I Eligible?

You May Qualify If You:

  • Are 18–80 years old
  • Have severe or uncontrolled asthma
  • Have had asthma exacerbations in the past year
  • Are on current asthma therapy
  • Are willing to attend regular study visits in Plantation, FL

You May NOT Qualify If You:

  • Have active lung infection
  • Have used certain biologics recently
  • Are pregnant or planning pregnancy
  • Have significant other medical conditions

Full eligibility criteria will be confirmed at your free screening visit. Call our research line to find out if you qualify.

Study Facts

Ages: 18–80
Sponsor: Sanofi
NCT: NCT06676319
Treatment: Bispecific antibody (lunsekimig)

Participation Benefits

  • Free investigational bispecific antibody therapy
  • Comprehensive asthma monitoring
  • Regular lung function testing
  • Expert pulmonologist care with Dr. Hull
  • Compensation for time and travel
  • Early access to innovative Sanofi therapy
Check Your Eligibility Call Research Line

ENDURA: IL-5 Inhibition for Eosinophilic COPD Exacerbators

Now Enrolling Eosinophilic COPD Precision Medicine

Targets the specific inflammatory pathway driving your COPD flare-ups. This precision medicine approach identifies COPD patients with elevated eosinophils most likely to benefit from targeted anti-eosinophilic treatment.

Study Overview

The ENDURA study evaluates IL-5 inhibition in carefully selected COPD patients with eosinophilic inflammation. This represents a precision medicine approach to COPD, targeting treatment to patients with specific inflammatory phenotypes who are most likely to respond. The study focuses on frequent exacerbators with elevated eosinophils ages 40-80.

Key Study Features

  • Targeted Therapy: For eosinophilic COPD only
  • IL-5 Inhibition: Reduces eosinophilic inflammation
  • Exacerbation Focus: For frequent exacerbators
  • Biomarker-Driven: Eosinophil and Type 2 markers
  • Personalized Approach: Precision medicine for COPD

Am I Eligible?

You May Qualify If You:

  • Are 40-80 years old
  • Have confirmed COPD with frequent exacerbations
  • Have elevated blood eosinophils
  • Have evidence of Type 2 inflammation
  • Are on optimal COPD therapy
  • Have history of ≥2 exacerbations yearly
  • Meet biomarker criteria

You May NOT Qualify If You:

  • Have primary asthma diagnosis
  • Have low eosinophil counts
  • Have received recent biologic therapy
  • Have active parasitic infection
  • Have immunodeficiency disorders
  • Are unable to use study medications

Study Facts

Ages: 40-80
Treatment: IL-5 antagonist
Focus: Eosinophilic COPD
Approach: Precision medicine

Participation Benefits

  • Targeted IL-5 therapy
  • Precision medicine approach
  • Regular eosinophil monitoring
  • Comprehensive COPD care
  • Biomarker assessments
  • Exacerbation prevention focus
  • Expert specialist management
Check Your Eligibility Call Research Line

THESEUS: Novel Nanobody Dual IL-13/TSLP Inhibition for COPD

Now Enrolling COPD Exacerbations Dual-Target Nanobody

Attacks COPD inflammation from two angles simultaneously. This revolutionary nanobody technology targets both IL-13 and TSLP pathways with a single molecule — designed for COPD patients with inadequate response to standard inhaled therapy.

Study Overview

The THESEUS study investigates an innovative nanobody that uniquely targets both IL-13 and TSLP inflammatory pathways simultaneously. Designed for moderate to very severe COPD patients with type-2 inflammatory phenotype and frequent exacerbations, this dual-action approach addresses multiple inflammatory mechanisms with a single therapy for ages 40-80.

Key Study Features

  • Dual Inhibition: Simultaneous IL-13 and TSLP blockade
  • Nanobody Design: Enhanced tissue penetration and stability
  • Exacerbation Focus: For high-risk COPD patients
  • Eosinophilic COPD: Particularly effective for elevated eosinophils
  • Inadequate Response: For those not responding to LAMA/LABA/ICS

Am I Eligible?

You May Qualify If You:

  • Are 40-80 years old
  • Have moderate to very severe COPD (≥12 months)
  • Have COPD with type-2 inflammatory phenotype
  • Post-bronchodilator FEV1 ≥20% and ≤70% predicted
  • Smoking history ≥10 pack-years
  • CAT score ≥10
  • ≥2 moderate or ≥1 severe exacerbation in past year
  • On triple therapy (LABA+LAMA+ICS) ≥3 months
  • Blood eosinophils ≥150 cells/μL

You May NOT Qualify If You:

  • Have asthma diagnosis
  • Have other significant lung diseases
  • Require oxygen >4.0 L/min
  • Recent COPD exacerbation (within 4 weeks)
  • Recent MI, TIA, or stroke (<6 months)
  • Heart failure NYHA Class III/IV

Study Facts

Duration: 48 weeks treatment
Visits: Monthly monitoring
Treatment: Subcutaneous nanobody
Focus: Exacerbation reduction

Participation Benefits

  • Free innovative nanobody therapy
  • Dual-pathway inflammation control
  • Regular lung function monitoring
  • Quality of life assessments
  • Comprehensive COPD management
  • Biomarker monitoring
  • Expert pulmonologist care
Check Your Eligibility Call Research Line

PRESTO: IRAK4 Inhibitor for COPD Inflammation

Now Enrolling COPD Novel Mechanism

Targets the upstream inflammatory signal driving COPD — a new mechanism. This first-in-class IRAK4 pathway inhibitor addresses chronic inflammation through toll-like receptors and IL-1 family pathways with a convenient oral tablet for patients with persistent airway inflammation.

Study Overview

The PRESTO study investigates an IRAK4 inhibitor that blocks key inflammatory signals in COPD. By targeting toll-like receptors and IL-1 family pathways, this oral medication addresses the underlying chronic inflammation that drives COPD progression and exacerbations. Designed for patients ages 40-80 with persistent airway inflammation despite maximal therapy.

Key Study Features

  • New Mechanism: IRAK4 inhibitor for COPD
  • Oral Therapy: Convenient tablet formulation
  • Inflammation Control: Targets TLR and IL-1 pathways
  • Exacerbation Prevention: Reduces inflammatory triggers
  • Disease Modification: Potential to slow progression

Am I Eligible?

You May Qualify If You:

  • Are 40-80 years old
  • Have moderate to very severe COPD ≥12 months
  • Have persistent airway inflammation despite maximal therapy
  • On stable triple or dual therapy ≥3 months
  • ≥2 moderate or ≥1 severe exacerbation in past year
  • Documentation of exacerbations available

You May NOT Qualify If You:

  • Have asthma or other lung diseases
  • Have unstable cardiovascular disease
  • Recent MI (<6 months)
  • Have active tuberculosis
  • Have HIV or hepatitis B/C
  • Have significant liver/kidney dysfunction

Study Facts

Ages: 40-80
Treatment: Oral IRAK4 inhibitor
Innovation: Novel mechanism for COPD
Visits: Regular monitoring

Participation Benefits

  • Access to novel IRAK4 inhibitor
  • Convenient oral medication
  • Comprehensive inflammation monitoring
  • Regular safety assessments
  • Exacerbation tracking
  • Potential disease modification
  • Expert COPD management
Check Your Eligibility Call Research Line

THARROS: Triple vs Dual Therapy for Cardiac Events in COPD

Now Enrolling COPD Cardiac Protection

Could triple therapy protect your heart and lungs better than dual therapy? This landmark Phase 3/4 study compares triple inhaled therapy versus dual therapy for reducing heart attacks and strokes in COPD patients with documented cardiovascular risk.

Study Overview

This pivotal study investigates whether adding an inhaled corticosteroid to dual bronchodilator therapy can significantly reduce major cardiovascular events in COPD patients at high cardiac risk. This study focuses not just on respiratory symptoms but on comprehensive cardiovascular protection for patients ages 40-80 with confirmed cardiovascular comorbidity.

Key Study Features

  • Cardiovascular Focus: Evaluating reduction in heart attacks and strokes
  • Comprehensive Protection: Dual lung and heart outcomes
  • Inflammation Control: Anti-inflammatory approach to systemic COPD effects
  • Risk Stratification: Focus on high cardiovascular risk patients
  • Long-term Outcomes: Extended follow-up for major cardiac events

Am I Eligible?

You May Qualify If You:

  • Are 40-80 years old
  • Have confirmed COPD diagnosis (FEV1/FVC ratio < 70%)
  • Have smoking history ≥10 pack-years
  • Have blood eosinophils ≥100 cells/mm³
  • Have CAT score ≥10
  • Have cardiovascular risk factors (prior heart attack, stents, or 3+ risk factors)

You May NOT Qualify If You:

  • Have asthma diagnosis
  • Are on long-term inhaled corticosteroids
  • Have severe liver or kidney disease
  • Have unstable cardiovascular conditions
  • Cannot use MDI devices properly
  • Have contraindications to study medications
  • Used maintenance inhaled corticosteroids (ICS) within the past 12 months

Study Facts

Duration: Up to 4 years follow-up
Visits: Every 3-6 months
Treatment: Triple or dual inhaled therapy
Primary Focus: Heart attack and stroke prevention

Participation Benefits

  • Free triple or dual combination inhaler therapy
  • Comprehensive cardiovascular monitoring
  • Regular cardiac biomarker testing
  • Advanced lung function assessments
  • Cardiovascular risk evaluation
  • Close monitoring by specialists
  • Contribution to landmark cardiac protection research
Check Your Eligibility Call Research Line

Exploring COPD clinical trials? Our comprehensive guide covers eligibility, what to expect, and how investigational treatments work.

COPD Clinical Trials Guide COPD Treatment Overview

VENTO: IL-33 Inhibition to Reduce Bronchiectasis Exacerbations

Now Enrolling Bronchiectasis Novel Biologic

May reduce the recurring infections driving your bronchiectasis flare-ups. This study investigates IL-33 inhibition as a new approach to reducing exacerbations in patients with confirmed bronchiectasis and frequent lung infections.

Study Overview

The VENTO study evaluates an IL-33 inhibitor for patients with confirmed bronchiectasis who experience recurrent pulmonary exacerbations. IL-33 is an alarmin cytokine involved in the inflammatory cascade that drives bronchiectasis flare-ups. By targeting this pathway, VENTO aims to reduce exacerbation frequency and improve quality of life for patients with this chronic lung condition.

Key Study Features

  • Novel Target: IL-33 inhibition to reduce airway inflammation
  • Exacerbation Focus: For patients with 2 or more flare-ups per year
  • Confirmed Bronchiectasis: HRCT diagnosis required
  • Infection Reduction: May reduce recurrent lung infections
  • Quality of Life: Focus on improving daily functioning

Am I Eligible?

You May Qualify If You:

  • Are 18-85 years old
  • Have confirmed bronchiectasis on HRCT scan
  • Have had 2 or more exacerbations in the past year
  • Have a history of recurrent lung infections
  • Are on stable bronchiectasis management therapy
  • Are able to provide informed consent

You May NOT Qualify If You:

  • Have cystic fibrosis
  • Have active pulmonary tuberculosis
  • Have had recent severe exacerbation requiring hospitalization
  • Are currently on immunosuppressive therapy
  • Have significant other medical conditions
  • Are pregnant or planning pregnancy

Study Facts

Ages: 18-85
Treatment: IL-33 inhibitor (biologic)
Focus: Exacerbation reduction
Requirement: HRCT-confirmed bronchiectasis

Participation Benefits

  • Free investigational IL-33 biologic therapy
  • Regular pulmonary function monitoring
  • Comprehensive exacerbation tracking
  • Quality of life assessments
  • Specialist respiratory care throughout study
  • Compensation for time and travel
  • Contribute to bronchiectasis research
Check Your Eligibility Call Research Line

CLEAR: Pseudomonas-Targeted Antibody for Bronchiectasis

Now Enrolling Bronchiectasis Novel Antibody

Targeting the Pseudomonas aeruginosa bacterial infection that drives chronic lung damage in bronchiectasis. The CLEAR study evaluates a new investigational antibody designed to help patients who have not been able to eliminate this persistent infection.

Study Overview

The CLEAR study is evaluating a new investigational antibody designed to help patients with bronchiectasis who have chronic Pseudomonas aeruginosa infection in their lungs. This type of bacterial infection is common in bronchiectasis and is associated with more frequent lung infections (exacerbations), hospitalizations, and worsening lung health over time.

This pseudomonal antibody is designed to target and block specific structures that Pseudomonas bacteria use to infect lung cells and form protective biofilms that make them harder for the immune system and antibiotics to eliminate. By disrupting these mechanisms, the CLEAR study aims to reduce lung flare-ups, improve respiratory symptoms, and potentially improve quality of life for people living with bronchiectasis.

Key Study Features

  • Novel Target: Antibody blocking Pseudomonas aeruginosa infection and biofilm formation
  • Exacerbation Reduction: Aims to reduce frequency of lung flare-ups
  • Infection Focus: For patients with confirmed chronic Pseudomonas colonization
  • Quality of Life: Focus on improving respiratory symptoms and daily functioning

Am I Eligible?

You May Qualify If You:

  • Are 12 years of age or older
  • Have confirmed bronchiectasis on CT scan (at least 1 lobe affected)
  • Have had 2 or more moderate exacerbations OR 1 severe (hospitalization) in the past 12 months
  • Have had a positive Pseudomonas aeruginosa airway sample at least once in the past 24 months
  • Have been clinically stable for at least 4 weeks prior to enrollment

You May NOT Qualify If You:

  • Have cystic fibrosis
  • Are not clinically stable at the time of enrollment
  • Have significant other medical conditions that may interfere with the study
  • Are pregnant or planning pregnancy

Study Facts

Ages: 12+
Treatment: Investigational Pseudomonas antibody
Focus: Exacerbation reduction in Pseudomonas-positive bronchiectasis
Requirement: CT-confirmed bronchiectasis + Pseudomonas history

Participation Benefits

  • Free investigational antibody therapy
  • Regular pulmonary monitoring and specialist care
  • Comprehensive exacerbation tracking
  • Quality of life assessments
  • Compensation for time and travel
  • Contribute to bronchiectasis research
Check Your Eligibility Call Research Line

Living with bronchiectasis? Learn about investigational treatments targeting the inflammation and infections that drive recurrent flare-ups.

Bronchiectasis Clinical Trials Guide Bronchiectasis Treatment Overview

Chronic Cough Research

Study Closed — Not Currently Recruiting

Our research center previously conducted a clinical trial for patients with chronic, unexplained cough lasting one year or more. That study has concluded.

We hope to bring additional chronic cough research opportunities to our patients in the future. If you have been living with a persistent cough that has not responded to standard treatments, we encourage you to check back periodically for updates on new trials as they become available.

For general inquiries, call our research line: 954-520-7296 x1

Referring Physicians: Enroll Your Patients in Active Research Studies

Lung Research Florida offers your patients access to advanced respiratory treatments across asthma, COPD, and bronchiectasis — including ultra-long-acting biologics, precision medicine, and novel anti-inflammatory approaches not available through standard care in South Florida.

Advanced Therapies

Ultra-long-acting biologics requiring only 2 injections yearly, dual-pathway nanobodies, and precision medicine for complex respiratory cases

Comprehensive Reporting

Detailed progress reports, biomarker analysis, and treatment outcomes shared with referring physicians throughout study participation

Fast-Track Enrollment

Same-day physician referral processing with eligibility assessment typically completed within 48 hours

View Physician Resources Call Research Referral Line

Interested in Participating in a Clinical Trial?

Our specialized research coordinators are available to discuss these studies and determine your eligibility. All consultations are free, confidential, and available in English and Spanish. Have questions about what clinical trials involve? Read our Clinical Trials FAQ for answers to the most common questions about participation, safety, and compensation.

Research Enrollment

954-520-7296 x1

Monday - Friday: 8:00 AM - 6:00 PM
Saturday: 9:00 AM - 2:00 PM

Email Research Team

Response within 4 hours during business days

Visit Our Research Center

Lung Research Florida
Research Facility of Advanced Asthma Clinic
10059 NW 1st Court
Plantation, FL 33324